Dennis J. Slamon
- Oncology top 0.01%
- HER2/EGFR in Cancer Research 174
- Cancer Treatment and Pharmacology 65
- Cancer-related Molecular Pathways 42
- Peptidase Inhibition and Analysis 28
- Cancer Research top 0.01%
- Breast Cancer Treatment Studies 38
- Cancer Genomics and Diagnostics 26
- Radiology, Nuclear Medicine and Imaging top 0.01%
- Monoclonal and Polyclonal Antibodies Research 87
- Pulmonary and Respiratory Medicine top 0.02%
- Advanced Breast Cancer Therapies 95
- Genetics top 0.05%
- Co-authors
- Axel UllrichSteven WongWendy J. LevinGary M. ClarkWilliam McGuireMark D. PegramMichael F. PressSteven Shak
- Partner nations
- United StatesGermanyCanada
In The Last Decade
Dennis J. Slamon
409 papers receiving 63.7k citations
Hit Papers
Peers
Comparison fields: 5 of 171
- Oncology 45.1k
- Cancer Research 13.9k
- Radiology, Nuclear Medicine and Imaging 18.7k
- Pulmonary and Respiratory Medicine 15.8k
- Genetics 4.5k
Countries citing papers authored by Dennis J. Slamon
This map shows the geographic impact of Dennis J. Slamon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dennis J. Slamon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dennis J. Slamon more than expected).
Fields of papers citing papers by Dennis J. Slamon
This network shows the impact of papers produced by Dennis J. Slamon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dennis J. Slamon. The network helps show where Dennis J. Slamon may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Dennis J. Slamon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2023 | 33 | |
| 3 | 2019 | 56 | |
| 4 | 2018 | 19 | |
| 5 | 2018 | 13 | |
| 6 | 2017 | 27 | |
| 7 | 2015 | 57 | |
| 8 | 2014 | 93 | |
| 9 | 2014 | 41 | |
| 10 | 2013 | 56 | |
| 11 | 2012 | 208 | |
| 12 | 2011 | 64 | |
| 13 | 2010 | 49 | |
| 14 | Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinomabreakdown → | 2010 | 923 |
| 15 | 2007 | 32 | |
| 16 | Advances in adjuvant therapy for breast cancer. | 2006 | 29 |
| 17 | Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancerbreakdown → | 2002 | 1508 |
| 18 | 1998 | 13 | |
| 19 | Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. | 1994 | 362 |
| 20 | Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. | 1990 | 143 |
About Dennis J. Slamon
Dennis J. Slamon is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 417 papers that have together received 65.5k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (174 papers), Advanced Breast Cancer Therapies (95 papers), Monoclonal and Polyclonal Antibodies Research (87 papers), Cancer Treatment and Pharmacology (65 papers), Cancer-related Molecular Pathways (42 papers), Breast Cancer Treatment Studies (38 papers), Peptidase Inhibition and Analysis (28 papers) and Cancer Genomics and Diagnostics (26 papers). The work is most often cited by research in Oncology (45.1k citations), Cancer Research (13.9k citations) and Radiology, Nuclear Medicine and Imaging (18.7k citations). Dennis J. Slamon has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Axel Ullrich, Steven Wong, Wendy J. Levin, Gary M. Clark, William McGuire, Mark D. Pegram, Michael F. Press, Steven Shak, Virginia Paton and Janet Wolter. Their work appears in journals such as Nature, Science and New England Journal of Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.